{"version":"1.0","provider_name":"Kuwait News Gazette","provider_url":"https:\/\/kuwaitnewsgazette.com","author_name":"kgadmin","author_url":"https:\/\/kuwaitnewsgazette.com\/author\/kgadmin\/","title":"Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine - Kuwait News Gazette","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"J1zF0nUIqD\"><a href=\"https:\/\/kuwaitnewsgazette.com\/merck-and-moderna-announce-exercise-of-option-by-merck-for-joint-development-and-commercialization-of-investigational-personalized-cancer-vaccine\/\">Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/kuwaitnewsgazette.com\/merck-and-moderna-announce-exercise-of-option-by-merck-for-joint-development-and-commercialization-of-investigational-personalized-cancer-vaccine\/embed\/#?secret=J1zF0nUIqD\" width=\"600\" height=\"338\" title=\"&#8220;Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine&#8221; &#8212; Kuwait News Gazette\" data-secret=\"J1zF0nUIqD\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"Companies on track to report data from the ongoing Phase 2 trial of mRNA-4157\/V940 in combination with KEYTRUDA\u00ae as adjuvant therapy in high-risk melanoma in 4Q 2022 CAMBRIDGE, MA and RAHWAY, NJ \/ ACCESSWIRE \/ October 12, 2022 \/\u00a0Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known [\u2026]"}